Glucopiericidin A is a natural piperidine-based compound found in marine-derived Streptomyces strains. It serves as a chemical probe for glucose transporter proteins (GLUT) and can inhibit glycolysis. When combined with Piericidin A (PA), it synergistically inhibits ATP-dependent filopodia formation, yet has no effect alone. Glucopiericidin A induces apoptosis by increasing PRDX1, thereby reducing reactive oxygen species (ROS) levels, and also demonstrates potent antitumor activity in ACHN mouse xenografts.

Glucopiericidin A exhibits cytotoxic effects against three renal carcinoma cell lines: ACHN with an IC50 of 0.21 μM, and OS-RC-2 and 786-O both with IC50 values exceeding 100 μM. It also affects a normal renal cell line, HK-2, with an IC50 greater than 100 μM [2]. In ACHN cells, Glucopiericidin A at concentrations of 25 and 50 nM for 24 hours leads to the upregulation of PRDX1, with increased mRNA and protein expression and translocation of PRDX1 into the nucleus [2]. Additionally, it reduces reactive oxygen species (ROS) levels in normal ACHN cells [2]. Neither Glucopiericidin A (GPA) nor Piericidin A (PA) alone, at concentrations up to 500 nM and 2.3 mM respectively, exhibit inhibitory activity. However, in combination, significantly lower concentrations of GPA (17 nM) and PA (0.68 nM) inhibit filopodia protrusion [1].

Administered intraperitoneally at a dosage of 0.8 mg/kg/day over three weeks, Glucopiericidin A significantly decreases the final tumor weight in nude mice bearing ACHN tumor xenografts [2]. Additionally, it enhances the mRNA and protein expression of PRDX1 within the tumor tissues.